- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03791086
The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping (BRIDGE)
The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping. An EMBARC2 and EMBARC3 Study
Bronchiectasis is a complex heterogeneous disorder. Treatment is challenging and many recent randomized controlled trials have been negative. It is believed that bronchiectasis as a broad diagnosis incorporates multiple different patient subgroups (also known as phenotypes) and molecular entities (referred to as endotypes). This study aims to phenotype and endotype bronchiectasis during stable disease and exacerbations, to develop strategies for personalised medicine.
Primary Objective To determine molecular endotypes of bronchiectasis which can guide response to treatment.
Secondary Objectives
- To determine molecular endotypes of stable bronchiectasis
- To determine the causes and inflammatory profiles of bronchiectasis exacerbations
- To validate candidate biomarkers of stable and exacerbation endotypes to use in stratified medicine
- To perform in-vivo or in-vitro proof of concept studies using phenotypic data to identify patient populations likely to benefit in future randomized controlled trials
This is an observational cohort study that will aim to identify patient subgroups and link these with meaningful clinical outcomes.
Study Overview
Status
Conditions
Detailed Description
Background: Bronchiectasis is a common disabling and heterogeneous disease that has been neglected in terms of basic and clinical research. Recent controlled trials have failed to achieve their primary end-points, likely because the optimal patient population to benefit from antibiotic, mucoactive and anti-inflammatory drugs has not been identified. This study aims to explore the clinical, microbiological, inflammatory and functional heterogeneity of the disease with the aim of identifying patient endotypes for stratified medicine.
Study aims and objectives
- To determine the molecular endotypes of bronchiectasis during stable disease
- To determine the causes and inflammatory profiles of bronchiectasis exacerbations
- To validate candidate biomarkers of stable and exacerbation endotypes to use in stratified medicine
- To perform in-vivo or in-vitro proof of concept studies using phenotypic data to identify patient populations likely to benefit in future randomized controlled trials Study Design: Observational Cohort study
Study methods:
Patients with bronchiectasis will be recruited into an observational study, the objectives of which will be to:
Aim 1 will define and validate endotypes of stable bronchiectasis by studying up to 1000 patients with bronchiectasis. Clinical data, sputum microbiome, sputum proteomics, and systemic and sputum inflammatory marker measurement will be incorporated for analysis. A sub-study (n=200) will be performed using air liquid interface culture of primary airway epithelial cells. Patients will have brushings of the inferior nasal turbinate with assessment of % ciliation, ciliary beat frequency and pattern by high speed video microscopy before and after culture.
Aim 2 will replicate the phenotyping approach to stable patients with 160 patients during exacerbation. This will identify changes from baseline in microbiota, proteomic and other markers associated with onset of exacerbation and allow classification of clusters of exacerbation.
Aim 3, we will externally validate candidate phenotype/endotypes in registered ethically approved external biobanks and aim to demonstrate that validated markers to be linked to potential treatment responses for use in stratified medicine trials.
In total we will recruit 1000 patients for study. These patients will attend the Clinical Research Centre at one of the participating study centres at least once and undergo sampling along with collecting of clinical data. Patients will be asked to consent for their samples to be linked to data held on the EMBARC registry.
Nature of outputs and outcomes/results expected:
This study will aim to establish detailed endotypes in bronchiectasis which can guide response to treatment.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Dundee, United Kingdom, DD1 9SY
- Recruiting
- University of Dundee
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and/or recurrent respiratory tract infections.
- A primary diagnosis of bronchiectasis made by a respiratory physician
- At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks.
Exclusion Criteria:
- Inability to give informed consent
- <18years of age
- Patients with active tuberculosis
- Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks
- Bronchiectasis due to cystic fibrosis
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients with bronchiectasis
Adult patients with bronchiectasis meeting the inclusion criteria.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of exacerbations
Time Frame: up to 3 years
|
Worsening of respiratory symptoms as defined by the EMBARC/BRR definition- Eur Respir J. 2017 Jun 8;49(6).
pii: 1700051.
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first exacerbation
Time Frame: 3 years
|
Time to first event after enrolment as defined by the EMBARC/BRR definition- Eur Respir J. 2017 Jun 8;49(6).
pii: 1700051.
|
3 years
|
Quality of life- the quality of life bronchiectasis questionnaire (QOL-B)
Time Frame: 3 years
|
Validated questionnaire
|
3 years
|
Quality of life- the St Georges Respiratory Questionnaire (SGRQ)
Time Frame: 3 years
|
Validated questionnaire
|
3 years
|
Quality of life- The Bronchiectasis impact measure (BIM)
Time Frame: 3 years
|
Questionnaire undergoing validation
|
3 years
|
Quality of life- The Bronchiectasis Health Questionnaire (BHQ)
Time Frame: 3 years
|
Validated questionnaire
|
3 years
|
Forced expiratory volume in 1 second (FEV1)
Time Frame: 3 years
|
Spirometry
|
3 years
|
Severity of disease (the bronchiectasis severity index)
Time Frame: 3 years
|
Validated severity assessment tool
|
3 years
|
Hospitalisation for severe exacerbations
Time Frame: 3 years
|
Admission to hospital for an exacerbation meeting the EMBARC/BRR exacerbation definition
|
3 years
|
All cause mortality
Time Frame: 3 years
|
Survival during the study
|
3 years
|
Infection with Pseudomonas aeruginosa
Time Frame: 3 years
|
Defined as isolation in sputum culture or bronchoalveolar lavage meeting the criteria for chronic infection- Ann Am Thorac Soc.
2015 Nov;12(11):1602-11.
|
3 years
|
Sputum volume
Time Frame: 3 years
|
Measured in millilitres per day
|
3 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017RC11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiectasis Adult
-
Ruijin HospitalAstraZeneca Investment (China) Co., LtdNot yet recruitingBronchiectasis AdultChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Azienda... and other collaboratorsActive, not recruiting
-
University of Sao Paulo General HospitalEnrolling by invitation
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedBronchiectasis AdultBrazil
-
University of North Carolina, Chapel HillCompletedBronchiectasis AdultUnited States
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingBronchiectasis Adult
-
Chang Gung Memorial HospitalNot yet recruitingBronchiectasis AdultTaiwan
-
Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedBronchiectasis AdultChina
-
Azienda Socio Sanitaria Territoriale della Valle...RecruitingCopd | Bronchiectasis AdultItaly
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruiting